Navigation Links
Valeritas Announces Appointment of New CEO
Date:6/1/2009

onsible for US, Canada, Nutravail, Business Development and New Product Planning. Earlier, Peterson spent 20 years with Bristol-Myers Squibb where she held assignments of increasing responsibility in sales, marketing and general management including running a Cardiovascular/Metabolics business unit and a generics division.

Peterson is currently a member of the Biotechnology Industry Organization Board (Health Governing Section) and a member of the Greater Philadelphia Life Sciences Congress Board. She is also an advisor to the Healthcare Businesswoman's Association Metro Chapter.

About Valeritas, Inc.

Valeritas is a medical technology company committed to developing and commercializing innovative drug delivery solutions that contribute to clinical and humanistic outcomes for patients, with an initial focus on the treatment of diabetes. Valeritas' medical technologies portfolio is headlined by the h-Patch(TM) Technology. The first use of the h-Patch(TM) technology will be the V-Go(TM) disposable insulin delivery device for continuous delivery both at a pre-set basal rate and for on-demand bolus dosing at mealtimes.

In addition to V-Go(TM), Valeritas' delivery technology portfolio includes the h-Patch(TM) for the delivery of other compounds beyond insulin, the Mini-Ject(TM) Pre-Filled Needle-Free Delivery System, and the Micro-Trans(TM) Microneedle Transdermal Delivery Patch. These technologies, when combined with certain compounds, are designed to provide unique products that allow precise dosing in previously difficult to treat conditions.

Headquartered in Parsippany, N.J., Valeritas operates its R&D and manufacturing in a state-of-the-art facility in Shrewsbury, Massachusetts. Valeritas primary investors include: MPM Capital, Pitango Venture Capital, Abingworth, US Venture Partners, Onset Ventures, Advanced Technology Ventures, HLM Venture Partners, CHL Medical Partne
'/>"/>

SOURCE Valeritas, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Valeritas Hires Trade and Distribution Industry Expert for the Launch of the h-Patch(TM) Disposable Insulin Delivery Device
2. Valeritas Hires Senior Account Management Industry Expert for the Launch of the h-Patch(TM) Disposable Insulin Delivery Device
3. John Timberlake, Valeritas Executive Vice President and General Manager, Named Executive of the Year by the Diabetes Foundation
4. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
5. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
6. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
7. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
8. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
9. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
10. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
11. Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... WriteResult®, a leading provider of Electronic Patient Outcome ... myPROpad™ ePRO tablet with the addition of a touchscreen ... widely used and well-respected Patient Reported Outcome (PRO) instruments ... used during clinical trials and in other health care ... to demonstrate Health-Related Quality of Life outcomes (HRQoL) resulting ...
(Date:8/19/2014)... Shimadzu Scientific Instruments has introduced two ... adding to the company’s extensive line-up of HPLC ... operating environment, and full automation, the i-Series provides ... conventional to ultra-high-speed analysis. , The ... so users can begin building the lab of ...
(Date:8/19/2014)... 2014 Cellgen Diagnostics ... to fund a corporate lab for its genetic-based ... development is a critical component in the move ... the implementation of personalized medicine – a more ... , Indiegogo contributions will support Cellgen’s intent to ...
(Date:8/19/2014)... (PRWEB) August 19, 2014 XenoTech ... fast and cost-effective metabolite production from bioactive small ... chemistry platform, the technology enables convenient and timely ... According to XenoTech’s Vice President of Commercial Operations, ... for assessing clinical risk can be measured directly ...
Breaking Biology Technology:EQ-5D™ Assessment Now Available for iPad 2Shimadzu’s New i-Series Integrated Liquid Chromatography Systems Provide Laboratories Wider Range of Analytical Capabilities 2Shimadzu’s New i-Series Integrated Liquid Chromatography Systems Provide Laboratories Wider Range of Analytical Capabilities 3Cellgen Diagnostics Launches Indiegogo Crowdfunding Campaign for DNA Medical Testing Device 2Cellgen Diagnostics Launches Indiegogo Crowdfunding Campaign for DNA Medical Testing Device 3Beyond Metabolite Identification, Testable Quantities Now Offered by XenoTech 2Beyond Metabolite Identification, Testable Quantities Now Offered by XenoTech 3
... ROCKVILLE, Md., Aug. 3, 2011 Neuralstem, Inc. (NYSE ... U.S. Department of Defense (DOD) contract to develop its ... cancerous brain tumors. The research contract, entitled "Research to ... be carried out in collaboration with Principal Investigator John ...
... Anadys Pharmaceuticals, Inc. (Nasdaq: ANDS ) announced today ... Monday, August 8, 2011, after the U.S. financial markets close. ... on Monday, August 8, 2011, at 5:00 p.m. Eastern Daylight ... highlights.  A live webcast of the call will be available ...
... CAMBRIDGE, Mass., Aug. 2, 2011 Pathogenica, Inc. announced ... is speaking today at the IBC Life Sciences Drug ... During the conference, the only event on the ... development, and patient care, Dr. Doran will speak on ...
Cached Biology Technology:Neuralstem Awarded Department of Defense Contract for Brain Cancer Research 2Neuralstem Awarded Department of Defense Contract for Brain Cancer Research 3Anadys Pharmaceuticals to Report Second Quarter 2011 Financial Results 2Pathogenica CSO Speaks at IBC Life Sciences Drug Discovery & Diagnostic Development Week 2
(Date:8/20/2014)... have developed methods for electronically manipulating the flight muscles ... use to control those muscles. The work opens the ... for use in emergency response. , "In the big ... the movement of moths for use in applications such ... an assistant professor of electrical and computer engineering at ...
(Date:8/20/2014)... , Aug. 20, 2014  The second ... place in Tampa, Florida ... sessions with Steven Rahman, Director, Technology and Strategy at ... at Experian. The theme of this year,s event ... Privacy. "Biometrics UnPlugged: Mobility at ...
(Date:8/19/2014)... supermarkets to encourage healthier spending habits? A new study ... question by tracking the purchasing records in a supermarket ... the nutritional value of foods for sale. , The ... PhD, and Brian Wansink PhD, author of Slim by ... Hannaford Supermarkets in the Northeastern United States between January ...
Breaking Biology News(10 mins):Research paves way for development of cyborg moth 'biobots' 2Biometrics UnPlugged: Mobility at the Crossroads of Commerce & Privacy to Feature Interactive Sessions with Samsung and Experian 2
... called ,pestilences, three are historically recognized as due to ... 19th to 21st centuries AD there were microbiological evidences ... pestis . "For a long time scholars from different ... of the past pandemics. Only ancient DNA analyses carried ...
... , May 9, 2013 Wexford Science & ... in the Wake Forest Innovation Quarter , today ... buildings currently underway represents an additional $150 million investment ... Wexford,s total investment in the Innovation Quarter to more ...
... NY and San Diego, CA A large, multi-institutional research ... a sweeping analysis in the current issue of the journal ... off to direct early human development. Led by Bing Ren ... The Salk Institute for Biological Studies and James Thomson of ...
Cached Biology News:Scientists confirm that the Justinianic Plague was caused by the bacterium Yersinia pestis 2Wexford Science & Technology Makes $150 Million Investment in Wake Forest Innovation Quarter 2Wexford Science & Technology Makes $150 Million Investment in Wake Forest Innovation Quarter 3Mapping the embryonic epigenome 2Mapping the embryonic epigenome 3
Human Legumain Affinity Purified Polyclonal Ab...
Human Cystatin F MAb (Clone 292103)...
... Ac-DEVD-CHO is an ... activity. The concentration of ... caspase activity must be ... system. Ten micromolar inhibitor ...
Human RELT/TNFRSF19L Affinity Purified Polyclonal Ab...
Biology Products: